Latest News and Information on Allergic Conjunctivitis

QLT Announces Phase II Clinical Trial Results and Development Plans for the ...
CNNMoney.com (press release)
A short-term, proof-of-concept study to evaluate the preliminary efficacy and safety of a sustained-release olopatadine PPDS for allergic conjunctivitis is ...
QLT Reveals Results From Phase II Clinical Trials, Device Study For Punctal ...RTT News

all 13 news articles »

Published on Wednesday 10th of March 2010 03:48:54 PM

QLT Inc. Q4 2009 Earnings Call Transcript
Seeking Alpha (blog)
This is a drug that's used to treat allergic conjunctivitis, and the overall allergic conjunctivitis market is large. It's about 50 million people just in ...
QLT Announces Fourth Quarter and Year End 2009 ResultsCNNMoney.com (press release)
QLT's Q4 profit boosted by sale of U.S. subsidiaryWinnipeg Free Press

all 55 news articles »

Published on Wednesday 10th of March 2010 03:48:54 PM

Inspire Reports Fourth Quarter and Full Year 2009 Financial Results
MarketWatch (press release)
... bacterial conjunctivitis, the co-promotion of ELESTAT(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on ...
Inspire Announces Webcast of Presentation at Cowen Health Care ConferencePharmiWeb.com (press release)

all 142 news articles »

Published on Wednesday 10th of March 2010 03:48:54 PM

Inspire Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare - Deals and ...
PR-inside.com (press release)
The company's product portfolio includes Elestat for the treatment of allergic conjunctivitis, Restasis for dry eye, and AzaSite for bacterial ...

and more »

Published on Wednesday 10th of March 2010 03:48:54 PM

Inspire Announces Date for Conference Call and Webcast to Discuss Fourth ...
MarketWatch (press release)
... the co-promotion of ELESTAT(R) (epinastine HCl ophthalmic solution) 0.05% for allergic conjunctivitis and royalties based on net sales of RESTASIS(R) ...

and more »

News: Allergic Conjunctivitis